Document ID: chunk:federal_register_of_legislation:F2020L01551:body:0:p10
Version: federal_register_of_legislation:F2020L01551
Segment Type: other
Provision Reference: 
Character Range: 30613–33293

the on-balance sheet exposures that relate to the book value of all equity investments in the ELE subsidiary.

          In column 5, report the on-balance sheet exposures that do not relate to equity investments in the ELE subsidiary for each exposure.

          In column 6, report the non-market related, off-balance sheet exposures for the ELE subsidiary for each exposure.

          In column 7, report the market related, off-balance sheet exposures for the ELE subsidiary for each exposure.

          Column 8 is derived as the total of columns 4, 5, 6 and 7 being the total exposure for the ELE subsidiary.

          Column 9 is derived as the ratio of column 8 to Tier 1 Capital reported in item 6.

Item 3.1  Item 3.1 is derived as the total of the ADI exposures to all ELE subsidiaries.

          Columns 4, 5, 6, 7 and 8 of item 3.1 are derived as the sum of columns 4, 5, 6, 7 and 8 of item 3 respectively.

          Column 9 of item 3.1 is derived as the ratio of column 8 of item 3.1 to Tier 1 Capital reported in item 6.

Item 4    Report exposures of all ELE subsidiaries which are established to hold or invest in assets, as at the end of the reporting period.

          In column 1, report the ELE subsidiary name for each exposure.

          In column 2, report the Legal Entity Identifier of the ELE subsidiary for each exposure. Otherwise, report N/A if the ELE subsidiary has no Legal Entity Identifier.

          In column 3, report the ELE subsidiary country of the ELE subsidiary for each exposure, using the country list.

          In column 4, report the on-balance sheet exposures that relate to the book value of all loans and advances of the ELE subsidiary for each exposure, including any accrued income associated with the exposure (e.g. interest, dividends).

          In column 5, report the on-balance sheet exposures that do not relate to loans and advances of the ELE subsidiary.

          In column 6, report the non-market related, off-balance sheet exposures of the ELE subsidiary for each exposure.

          In column 7, report the market related, off-balance sheet exposures of the ELE subsidiary for each exposure.

          Column 8 is derived as the total of columns 4, 5, 6 and 7 being the total exposure of each ELE subsidiary.

          Column 9 is derived as the ratio of column 8 to Tier 1 Capital reported in item 6.

Item 4.1  Item 4.1 is derived as the total of the exposures of all ELE subsidiaries.

          Columns 4, 5, 6, 7 and 8 of item 4.1 are derived as the sum of columns 4, 5, 6, 7 and 8 of item 4 respectively.

          Column 9 of item 4.1 is derived as the ratio of column